Smaptars triad
Reading File
Searching the Web
Samter's triad AERD diagnosis treatment 2024
Finding Sources
Searching PubMed
aspirin exacerbated respiratory disease AERD Samter triad
Reading File
Searching PubMed
aspirin exacerbated respiratory disease treatment
Reading File
Reading File
Here is a complete overview of Samter's Triad (AERD - Aspirin-Exacerbated Respiratory Disease):
Samter's Triad (AERD)
Definition
Samter's Triad is a clinical syndrome first described by Widal in 1922 and formally characterized by Samter et al. in 1967. It consists of three co-existing features:
| Component | Details |
|---|---|
| 1. Bronchial Asthma | Adult-onset, often moderate-to-severe, non-atopic |
| 2. Chronic Rhinosinusitis with Nasal Polyps | Extensive polyposis, highly recurrent |
| 3. Aspirin/NSAID Sensitivity | Respiratory reactions triggered by COX-1 inhibitors |
The diagnosis is clinical: asthma + nasal polyps + respiratory reactions to NSAIDs is sufficient. If the NSAID reaction history is unclear, a formal aspirin challenge confirms it.
Epidemiology
- Prevalence: up to 0.3% of the general population
- Found in 5-10% of the adult asthmatic population
- About 9% of all adults with asthma; 30% of those with asthma AND nasal polyps
- More common in patients over 40 years old
- Patients are typically non-atopic (not classically allergic)
- Affects >1 million people in the US
Pathophysiology
The mechanism centers on dysregulated arachidonic acid metabolism due to COX-1 inhibition:
- COX-1 blockade by aspirin/NSAIDs shunts arachidonic acid away from prostaglandin synthesis
- Lipoxygenase pathway overactivation - markedly increased production of cysteinyl leukotrienes (LTC4, LTD4, LTE4)
- Reduced Prostaglandin E2 (PGE2) - normally serves as a "brake" on mast cells and eosinophils; its absence leads to mast cell instability
- Histamine release + elevated leukotrienes together cause:
- Increased vascular permeability
- Tissue edema
- Bronchoconstriction
- This chronic cycle of inflammation and edema is thought to drive nasal polyp formation
The disease also involves type 2 inflammation (eosinophilic), independent of COX-1 inhibition.
Clinical Features
- Asthma: typically progressive, may be severe
- Nasal polyps: extensive, bilateral; CT scores significantly higher than non-AERD polyp patients
- NSAID reactions: occur within minutes to hours of ingestion - rhinorrhea, bronchospasm, urticaria
- Anosmia/hyposmia: common due to extensive nasal polyposis
- Symptoms often resistant to conventional therapy
Nasal Polyp Behavior in AERD
AERD polyps are notably aggressive. A cohort study of 549 patients with nasal polyposis found polyp-free rates at 5 years post-FESS (functional endoscopic sinus surgery):
- Controls: 84% polyp-free
- Asthma-only patients: 55% polyp-free
- AERD patients: 10% polyp-free
At 10 years, 100% of AERD patients had recurred - Scott-Brown's Otorhinolaryngology, Vol. 1
Treatment
| Modality | Notes |
|---|---|
| Aspirin desensitization | Most effective known treatment; incrementally increasing aspirin doses until several hundred mg/day tolerated; improves both nasal and pulmonary symptoms, reduces steroid use |
| Low-dose aspirin (100 mg) | Placebo-controlled RCT showed reduction in polyp recurrence |
| Leukotriene modifiers | Montelukast, zileuton; directly target the overactive lipoxygenase pathway |
| Intranasal/oral corticosteroids | Mainstay for polyp management |
| FESS | Surgical debulking; does not cure AERD; high recurrence rate |
| Biologics | Dupilumab (anti-IL-4/IL-13), mepolizumab (anti-IL-5) - emerging treatments targeting type 2 inflammation |
| Avoid NSAIDs/aspirin | Unless desensitization is planned under supervision |
Important: Antihistamines and allergy shots have limited benefit in AERD, as the disease is not primarily driven by IgE/environmental allergies (though ~50% of AERD patients have coexisting environmental allergies).
Note on desensitization: If polyps recur and require surgery, aspirin is typically discontinued, and the desensitization process must be repeated afterward. Topical lysine aspirin has been studied but showed no significant clinical benefit in controlled trials.
Anesthetic Relevance
In surgical settings, NSAIDs including ketorolac are contraindicated in patients with Samter's Triad due to the risk of acute bronchospasm - Miller's Anesthesia, 10e
Sources: Scott-Brown's Otorhinolaryngology Head & Neck Surgery Vol. 1 | K.J. Lee's Essential Otolaryngology | Miller's Anesthesia 10e | AAAAI overview | Samter's Society treatment guide
This is a shared conversation. Sign in to Orris to start your own chat.